ArticleBMC cancer2025
Evaluation of the association between lymph node ratio and long-term survival in patients after surgery for lymph node-positive bladder cancer: a SEER population-based study with external validation.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Integration of Single-cell and bulk RNA sequencing data uncovers lymphatic metastasis-related prognostic genes and a predictive model in bladder cancer.Scientific reports · 2025Article
- A log odds of positive lymph nodes (LODDS)-based nomogram for survival prediction in elderly bladder cancer patients after radical cystectomy: development and validation using SEER and Chinese cohorts.Translational andrology and urology · 2025Article
- The Impact of Lymph Node Ratio for Children with Wilms Tumors: A National Cancer Database Analysis.Cancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe lymph node ratio (LNR) has been recognized as an emerging prognostic biomarker in various malignant tumors. Our study aimed to investigate the prognostic role of LNR in postoperative patients with lymph node-positive bladder cancer.
methodsThis study comprised a total of 3911 eligible patients diagnosed with lymph node-positive bladder cancer. This included 3767 patients from the Surveillance, Epidemiology, and End Results (SEER) database and 144 patients from two Chinese hospitals forming the external validation cohort. We used X-tile software to identify the optimal cut-off value for LNR. The Kaplan-Meier method and Cox regression model were utilized to evaluate the association between LNR and overall survival (OS) and cancer-specific survival (CSS). Based on the LNR index, two nomograms were constructed to estimate the prognosis of patients with lymph node-positive bladder cancer. The discriminant ability and accuracy of the nomogram were tested using the receiver operating characteristic (ROC) curve, calibration curves and decision curve analysis.
resultsThe Kaplan-Meier survival curves, stratified by LNR, demonstrated significant differences in overall and cancer-specific survival rates (P < 0.05). After adjusting for clinical and tumor factors, including AJCC N staging, patients with an LNR greater than 0.3 exhibited significantly worse OS and CSS compared to those with an LNR less than 0.1 in both the SEER and external validation cohorts. Furthermore, the nomogram, which incorporated LNR, showed satisfactory discriminative ability, and the calibration curves confirmed favorable consistency.
conclusionLNR proves to be an independent prognostic factor for postoperative patients with lymph node-positive bladder cancer. These findings highlight LNR's potential as a prognostic indicator, which could be beneficial in patient consultations and guiding treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.